Dr. Reddy's Laboratories secured U.S. FDA approval for its rituximab biosimilar on August 1, 2026, following a successful inspection of its Hyderabad facility. Fresenius Kabi will exclusively commercialize the drug in the United States, adding to Dr. Reddy's existing presence in Europe, India, and emerging markets. The approval validates the company's capabilities in complex biologics development.